

Date: June 29, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Outcome of Board Meeting of the Company held on Monday, June 29, 2026

Dear Sir/Madam,

In Compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held today, i.e., Monday, June 29, 2026 has considered and approved the proposed variation in the utilisation of unutilised portion of the Initial Public Offer (“**IPO**”) proceeds to the extent of ₹ 1000.16 million out of the total primary IPO proceeds of ₹ 5000.00 million, subject to the approval of Shareholders through Postal Ballot.

The meeting of the Board of Directors of the Company commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M.(IST)

The aforesaid intimation is also being hosted on the website of the Company.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Deval Rajnikant Shah
Whole Time Director & CFO
DIN:00332722

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263